479306
cis-Diamineplatinum(II) dichloride
≥99.9% trace metals basis
동의어(들):
cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
Linear Formula:
Pt(NH3)2Cl2
CAS 번호:
Molecular Weight:
300.05
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12161600
EC Number:
239-733-8
MDL number:
Quality Level
assay
≥99.9% trace metals basis
reaction suitability
core: platinum, reagent type: catalyst
mp
270 °C (lit.)
antibiotic activity spectrum
neoplastics
mode of action
DNA synthesis | interferes
SMILES string
N.N.Cl[Pt]Cl
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
InChI key
LXZZYRPGZAFOLE-UHFFFAOYSA-L
Application
cis-Diamineplatinum(II) dichloride can be used as a model drug to test the efficiency of various drug carriers in drug delivery.
Highly active chemotherapeutic agent for use in preventing the advancement of testicular cancer.
Biochem/physiol Actions
Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.
signalword
Danger
target_organs
Respiratory system
저장 등급
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy.
Xu P, et al.
Colloids and Surfaces. B, Biointerfaces, 48(1), 50-57 (2006)
Synthesis of a new nanoparticle system based on electrostatic alginate?piperazine interactions.
Roman JV, et al.
Polymers For Advanced Technologies, 27(5), 623-629 (2016)
Pedro J Beltran et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(11), 2947-2958 (2014-04-15)
Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal antibody against IGF-IR. Here, we explore the therapeutic potential of ganitumab for the treatment of ovarian cancer. The
Koji Tanaka et al.
Carcinogenesis, 36(8), 894-903 (2015-05-31)
There is increasing evidence that the expression of microRNA (miRNA) in cancer is associated with chemosensitivity but the mechanism of miRNA-induced chemoresistance has not been fully elucidated. The aim of this study was to examine the role of extracellular miRNA
Abdullah A Osman et al.
Cancer research, 75(7), 1205-1215 (2015-02-19)
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.